Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by qwerty22on Oct 13, 2022 10:57pm
436 Views
Post# 35024012

Finally listened to call

Finally listened to call

I was going on people reaction here before.

I thought the call was fine apart from no ongoing trial update.

There was one nugget when Christian seems to suggest that all the main cancers in the trial had over 85% Sortilin expression. He seemed to suggest that was what the up and coming microarray poster would say. If that's true then that is great, in fact fantastic. The worry that they are enrolling significant SORT- patients is really off the table now. It also makes screening for Sortilin less of a priority for now. That's great news.

The other good point for me is Christian clear said the protocol going forward is see two responders from upto 10 patients, expand to 25 and then move forward to the next phase if they have the data to support that. 

They obviously made a prior decision not to discuss the ongoing trial. My take is it is hitting that 2 responders from 10 that triggers the next update especially if that triggers a quick expansion to 25. So this is what we should be expecting. Should that have happened by now? I don't think so necessarily. If no one cancer type has aggressively enrolled then they could have a mish mash of results where none of those quite reach that go signal benchmark. I guess we have to accept they aren't going to dribble out results on every responder leading up to that point.

I can sort of even understand why they don't want to talk about enrolment rates. If you say it's slow, then that's a negative. If you say it's fast and aren't releasing details on responders then it looks like the drug is a dud.

I think the one conclusion we can say is the probably haven't hit the go signal yet. I'm not too bothered (yet) about the trial being a dud. I'm putting this down to our expectations being too high about was is possible yet. You sort of have to admire their discipline is saying nothing about the ongoing trial. It sucks but they clearly decided to say nothing and they did it well.

On other things. I thought they contextualized the NASH situation the way I understand it. I also thought they inspired a bit more hope that the Trogarzo management plan could yield some potential benefits (eventually). 

<< Previous
Bullboard Posts
Next >>